Health Care & Life Sciences » Pharmaceuticals | YiChang HEC ChangJiang Pharmaceutical Co. Ltd.

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. | Mutual Funds

Mutual Funds that own YiChang HEC ChangJiang Pharmaceutical Co. Ltd.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Baring International Umbrella Fund - Hong Kong China Fund
3,075,000
1.36%
0
0.74%
10/31/2017
Fidelity China Region Fund
2,908,400
1.29%
0
1.05%
07/31/2018
iShares Core MSCI Emerging Markets ETF
2,560,000
1.12%
0
0.02%
09/05/2018
Vanguard Emerging Markets Stock Index Fund
2,164,593
0.96%
-14,000
0.01%
07/31/2018
Vanguard Total International Stock Index Fund
2,138,331
0.95%
0
0%
07/31/2018
Oberweis International Opportunities Institutional Fund
1,498,800
0.66%
1,498,800
0.67%
03/31/2018
Oberweis International Opportunities Fund
1,303,200
0.57%
1,303,200
0.67%
03/31/2018
CREF Stock Account
1,010,000
0.45%
0
0%
03/31/2018
Huaan Hong Kong Selection Stock Fund
976,400
0.43%
88,000
3.19%
12/31/2017
LMCG Emerging Markets Collective Fund
828,600
0.37%
828,600
0.5%
06/30/2018

About YiChang HEC ChangJiang Pharmaceutical Co.

View Profile
Address
Dong YangGuang Park
Dongguan Guangdong 443300
China
Employees -
Website http://www.hec-changjiang.com
Updated 07/08/2019
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. engages in the development, manufacturing and selling of pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, cardiovascular diseases and others. Its products include Benzbromarone, Telmisartan, Amlodipine besylate, and Cetirizine hydrochloride. The company was founded on May 11, 2015 and is headquartered in Dongguan, China.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.